A First-Line Challenger: What MAPLE-HCM Means for the Clinic

The MAPLE-HCM data are cleaner than expected — but a 24-week trial of 175 patients cannot yet rewrite guideline-recommended first-line therapy for obstructive HCM.

Armando Cuesta, MD Wednesday, 10 June 2026 · 2 min read

Analysis. Drafted by The Vital Record’s AI under Armando Cuesta, MD’s direction and reviewed by him before publication. How we label →

Until MAPLE-HCM, the argument for aficamten over a beta-blocker in obstructive hypertrophic cardiomyopathy rested on mechanism and on SEQUOIA-HCM — a 28-week placebo-controlled trial. Compelling, but placebo comparisons cannot answer the question cardiologists actually face at the prescription pad: is the newer, more expensive, REMS-restricted drug better than what is already there?

MAPLE-HCM answers that question, at least within its 24-week window and 175-patient scope. A 2.3 mL/kg/min peak VO₂ treatment difference is not noise. That magnitude of improvement in cardiopulmonary exercise capacity — a direct, objective, patient-relevant measure — correlates with reduced hospitalization and improved prognosis in heart failure populations. Add 51% versus 26% for NYHA class improvement, an −81% differential in NT-proBNP, and substantial reductions in resting and Valsalva LVOT gradient, and you have a consistent, multi-axis signal.

“For the first time we have a fair fight — aficamten versus what we actually prescribe — and aficamten won decisively.” — Dr. Pablo García-Pavia, MAPLE-HCM principal investigator, ESC Congress 2025

The caveats matter. This was a 24-week trial; obstructive HCM is a decades-long disease. Aficamten’s boxed warning for systolic dysfunction means every patient needs echocardiographic surveillance under the MYQORZO REMS, which adds friction and cost. The MAPLE-HCM population was symptomatic NYHA class II–III adults with LVOT obstruction — the benefit may not extrapolate to minimally symptomatic, non-obstructive, or end-stage disease.

There is also an access question. Metoprolol costs pennies per day. Aficamten’s price creates a structural barrier that the efficacy data alone cannot dissolve. Guideline committees will need to weigh outcomes, monitoring burden, and real-world access in the same frame — not sequentially.

What MAPLE-HCM does establish is that aficamten is the empirically superior pharmacological option for symptomatic obstructive HCM in patients who are candidates for the drug. The guideline update conversation begins now, with the caveat that converting a 24-week head-to-head trial into a durable first-line recommendation requires longer safety data than we currently have.

This analysis column is AI-drafted under Armando Cuesta, MD’s editorial direction.